Eli Lilly has entered into a multi-year research and licensing agreement with Nimbus Therapeutics to develop next-generation oral treatments for obesity and related metabolic disorders. Under the deal, Nimbus will apply its proprietary artificial intelligence platform to identify novel small-molecule targets, while Lilly will lead preclinical development and commercialization. The agreement includes upfront payments to Nimbus totaling $100 million, and potential milestone payments that could exceed $1 billion, underscoring Lilly’s commitment to expanding its obesity portfolio beyond injectable therapies.

Lilly’s dual-brand tirzepatide franchise – marketed as Mounjaro for type 2 diabetes and Zepbound for weight management – delivered combined sales exceeding $10 billion in the most recent quarter, contributing to a 54 percent year-over-year increase in total company revenue. This performance has propelled Lilly’s market capitalization to approximately $960 billion, just shy of the unprecedented $1 trillion threshold. Over the past three years, Lilly’s share count has remained largely stable, resulting in nearly 200 percent total return for investors, driven primarily by escalating demand for its weight-loss therapies.

Lilly’s late-stage oral GLP-1 receptor agonist, currently under regulatory review, is distinguished by its lack of mandated dietary restrictions—a feature not offered by rival oral formulations. Analysts forecast the global weight-loss market to approach $100 billion by 2030, and Lilly’s potential first-mover advantage in a truly flexible pill could capture a significant share. In head-to-head trials, injectable tirzepatide demonstrated superior efficacy to Novo Nordisk’s weekly competitor, and investors anticipate similar outperformance from Lilly’s oral candidate, which is enrolled in a Phase 3 cardiovascular outcomes study involving more than 8,000 participants.